Eli Lilly and Novo Nordisk plan to launch weight loss drugs in India by 2025

Eli Lilly and Novo Nordisk plan to launch their weight loss drugs, semaglutide and tirzepatide, in India by 2025. These drugs, initially designed for diabetes management, have shown significant benefits in reducing obesity and related chronic conditions. Recent trials revealed that tirzepatide can lower heart failure outcomes by 38% and reduce the risk of diabetes in pre-diabetic individuals by 94%. Semaglutide has also demonstrated a 24% reduction in kidney disease progression and improved liver health. While these drugs can cause gastrointestinal side effects, their overall benefits in weight loss and chronic disease management are notable. Generic versions of semaglutide are expected in India after its patent expires in 2026.